Intellia Therapeutics presented clinical updates on its in vivo gene‑editing programs at ESGCT, reporting durable pharmacodynamic effects and safety signals across multiple trials. The company highlighted NTLA‑2002 (hepatic-targeted LNP program for hereditary angioedema) and its ATTR program as the most advanced, with sustained target knockdown measured months after dosing. Intellia emphasized advantages of lipid nanoparticle (LNP) delivery — scalable manufacturing, transient expression, and potential for redosing — and reviewed safety monitoring in treated cohorts. LNP‑delivered in vivo editing remains a central industry approach to reach hepatically driven diseases without viral vectors.